Response rate in patients treated with daratumumab plus pom-dex. (A) Overall response rate. (B) Subgroup analysis of the overall best response. The dashed vertical line indicates 60.2%, which was the ORR in the total patient cohort. Exact 95% CIs are provided. ^aClassified as mild (total bilirubin 1.0-1.5× upper limit of normal or aspartate aminotransferase above upper limit of normal), moderate (total bilirubin >1.5-3.0× upper limit of normal), or severe (total bilirubin >3.0× upper limit of normal); 17% had mild impairment; 1% had moderate impairment; 0% had severe impairment. Patients with impaired hepatic function received fewer doses of daratumumab vs patients with normal hepatic function. ^bThe discrepancy with the demographics table is due to updated concomitant medication data. CrCl, creatinine clearance; DARA, daratumumab; sCR, stringent complete response.